Advagene Biopharma Past Earnings Performance
Past criteria checks 0/6
Advagene Biopharma's earnings have been declining at an average annual rate of -3.9%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually.
Key information
-3.9%
Earnings growth rate
0.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | n/a |
| Return on equity | -70.8% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Advagene Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -77 | 20 | 58 |
| 31 Mar 24 | 0 | -84 | 20 | 66 |
| 31 Dec 23 | 0 | -92 | 20 | 73 |
| 30 Sep 23 | 0 | -101 | 20 | 82 |
| 30 Jun 23 | 0 | -109 | 19 | 91 |
| 31 Mar 23 | 0 | -114 | 20 | 96 |
| 31 Dec 22 | 0 | -118 | 20 | 100 |
| 30 Sep 22 | 0 | -114 | 20 | 95 |
| 30 Jun 22 | 0 | -109 | 21 | 90 |
| 31 Mar 22 | 0 | -101 | 21 | 81 |
| 31 Dec 21 | 0 | -93 | 22 | 73 |
| 30 Sep 21 | 0 | -85 | 22 | 67 |
| 30 Jun 21 | 0 | -78 | 22 | 62 |
| 31 Mar 21 | 0 | -74 | 21 | 59 |
| 31 Dec 20 | 0 | -70 | 20 | 55 |
| 30 Sep 20 | 0 | -79 | 24 | 62 |
| 30 Jun 20 | 0 | -89 | 27 | 69 |
| 31 Mar 20 | 0 | -90 | 28 | 70 |
| 31 Dec 19 | 0 | -92 | 28 | 71 |
| 30 Sep 19 | 0 | -87 | 26 | 72 |
| 30 Jun 19 | 0 | -82 | 24 | 73 |
| 31 Mar 19 | 0 | -97 | 22 | 89 |
| 31 Dec 18 | 0 | -111 | 20 | 105 |
| 30 Sep 18 | 0 | -132 | 18 | 128 |
| 30 Jun 18 | 0 | -153 | 15 | 150 |
| 31 Mar 18 | 0 | -146 | 17 | 140 |
| 31 Dec 17 | 0 | -138 | 19 | 131 |
| 31 Dec 16 | 0 | -91 | 27 | 64 |
Quality Earnings: 6709 is currently unprofitable.
Growing Profit Margin: 6709 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6709 is unprofitable, and losses have increased over the past 5 years at a rate of 3.9% per year.
Accelerating Growth: Unable to compare 6709's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6709 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.9%).
Return on Equity
High ROE: 6709 has a negative Return on Equity (-70.83%), as it is currently unprofitable.